Companies

ALNY · Biotech

ALNYLAM PHARMACEUTICALS, INC.

SEC company filings

Reported cash

USD 1,754,340,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Clinical readout window

ALN-2232 · clinical data · February 2027

obesity and weight management

Phase 1

Announced Oct 29, 2026 · Announced window

Official announcement
Source wording

The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of ALN-2232 in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027.

Clinical readout window

ALN-6400 · clinical data · February 2027

hereditary hemorrhagic telangiectasia (HHT)

Phase 2

NCT06659640

Announced Oct 29, 2026 · Announced window

Official announcement
Source wording

The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1 trial of ALN-2232 in obesity and weight management, in conjunction with its fourth quarter and full year 2026 earnings call in February 2027.

Drug pipeline

0 programs · 0 verified studies

No verified studies linked yet.

95 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.